ATX code V03AB32 Indications for use prevention of neurotoxicity during chemotherapy with cisplatin or other related compounds List of information required before use Contraindications hypersensitivity to the active substances or to any of the excipients Necessary precautions for use In case of adverse reactions during intravenous administration, use of the drug should be discontinued immediately
Jennifer McCauley, a weight management physician at UNC Health, said Medicaid coverage of GLP-1s was incredibly helpful for our patients. Now theyve stopped coverage, so those people are now going back, regaining some of the weight, because theyre unable to obtain these medications, and also are suffering the health consequences of obesity, McCauley told Stateline
25 However, the specific contribution of the GIPR and GLP-1R to the pharmacological effects of dual incretin receptor agonism are currently undetermined
The Specialist Pharmacy Service (SPS) advises that DPP-4 inhibitors should generally be discontinued when initiating a GLP-1 receptor agonist due to their overlapping mechanisms and limited additional benefit